AnGes, Inc.

$47 JPY

$0 (0.0%)

Volume: 651.5K
Average Volume: 1.34M
Market Capitalization: $18.59B
P/E Ratio: -3.33
Dividend Yield: 0.00%
Price Target

Year High: $120.00
Year Low: $44.00
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $1.97

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecast Upside/Downside	%
Consensus Rating	Strong Sell
Rating Score(0-5)	1
Research Coverage	0 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$14.44
Trailing P/E Ratio	-3.33
PEG Ratio	-0.03
P/E Growth	-0.03
Net Income	-$5.12B
Net Margin	-545.66%
Pretax Margin	-562.28%
Return on Equity	-156.47%
Return on Assets	-110.87%

Financials Score

AltmanZ Score	-16.08
Piotroski Score	3.00
Working Capital	1.66B
Total Assets	4.47B
Ebit	-6.48B
Market Cap	18.59B
Total Liabilities	2.45B

Company Executives

Name	Title
Naoya Sato	Director of Administration & Director
Yuka Murakami	Accounting Department Manager
Ei Yamada	Chief Executive Officer, President & Representative Director

About AnGes, Inc. (JPX:4563.T) Stock

AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Plasmid, an innovative gene therapy designed to address critical limb ischemia, a severe circulatory condition impacting the legs. The company's diverse pipeline also includes NF-kB Decoy Oligonucleotide, a nucleic acid medicine formulated to suppress inflammation for various ailments, including low back pain. Furthermore, AnGes is actively developing treatments for atopic dermatitis and disc degeneration, as well as specialized medical devices aimed at preventing vascular restenosis. Their development endeavors also extend to therapeutic vaccines fo ... r cervical intraepithelial neoplasia, a precursor to cervical cancer, and, through a research partnership with Osaka University, DNA vaccines targeting hypertension. AnGes fosters strategic alliances to expand its global reach and product commercialization. These collaborations include BioMarin Pharmaceutical Inc. for the Japanese market distribution of Naglazyme, a drug for mucopolysaccharidosis VI; and Mitsubishi Tanabe Pharma Corporation, which handles the marketing of HGF Plasmid for peripheral arterial disease in both the United States and Japan. Other key partners are SHIONOGI & CO., LTD. for the commercialization of topical NF-kB decoy oligonucleotide drugs for dermatological conditions, and Vical, Inc. for the development and marketing of Allovectin, a cancer treatment. Additionally, AnGes has joined forces with Osaka University to develop a coronavirus vaccine, and with Brickell Biotech, Inc. for an investigational plasmid DNA vaccine intended to prevent coronavirus across the U.S., South America, and other territories. The company, previously known as AnGes MG, Inc., officially rebranded to AnGes, Inc. in July 2017.

Frequently Asked Questions

What is the current AnGes, Inc. (4563.T) stock price?: AnGes, Inc.(JPX:4563.T) stock price is $47 in the last trading session. During the trading session, 4563.T stock reached the peak price of $120 while $44 was the lowest point it dropped to. The percentage change in 4563.T stock occurred in the recent session was 0.0% while the dollar amount for the price change in 4563.T stock was $0.
4563.T's industry and sector of operation?: The JPX listed 4563.T is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of 4563.T?: Naoya Sato | Director of Administration & Director
Yuka Murakami | Accounting Department Manager
Ei Yamada | Chief Executive Officer, President & Representative Director
|
|
How many employees does 4563.T have?: Number of 4563.T employees currently stands at 56. 4563.T operates from Saito Bio-Incubator, Ibaraki, OS 567-0085, JP.

Link for 4563.T official website?: Official Website of 4563.T is: https://www.anges.co.jp
How do I contact 4563.T?: 4563.T could be contacted at phone #+81 72 641 8011 and can also be accessed through its website. 4563.T operates from Saito Bio-Incubator, Ibaraki, OS 567-0085, JP.
How many shares of 4563.T are traded daily?: The average number of 4563.T shares traded daily for last 3 months was 1.34M.
What is the market cap of 4563.T currently?: The market value of 4563.T currently stands at $18.59B with its latest stock price at $47

Enter your email address below for free access to our AnGes, Inc. (4563.T) research center and poll results.

AnGes, Inc.

$47 JPY

Company Overview

Liquidity Metrics

Sales & Valuation

Profitability

P/E Metrics

Analyst Price Target & Rating

Financial Health Scores

Key Metrics (TTM)

Company Executives

Poll Results